Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis
Expert Opinion on Investigational Drugs · 03.07.2026 · 35 (7) · 481-483
DOI: 10.1080/13543784.2026.2698521 ↗Kurz gefasst
Editorial in der Zeitschrift Expert Opinion on Investigational Drugs, online erschienen am 05.07.2026. Verfasst von Burhan A Buttar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
- Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
- Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
ORCID-Profile: Burhan A Buttar
Zitieren
APA
Buttar, B. A., Subhash, S., & Feldman, S. R. (2026). Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis. Expert Opinion on Investigational Drugs, 35(7), 481-483. https://doi.org/10.1080/13543784.2026.2698521
Vancouver
Buttar BA, Subhash S, Feldman SR. Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis. Expert Opinion on Investigational Drugs. 2026;35(7):481-483. doi:10.1080/13543784.2026.2698521
BibTeX
@article{Buttar2026,
author = {Buttar, Burhan A and Subhash, Sanat and Feldman, Steven R},
title = {Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis},
journal = {Expert Opinion on Investigational Drugs},
year = {2026},
volume = {35},
number = {7},
pages = {481--483},
doi = {10.1080/13543784.2026.2698521}
}
EUVIMED